Denis Odinokov’s Post

🔬 Delving into the Frontiers of Pancreatic Cancer Immunotherapy! 📝 I am thrilled to share again our review article, "The Clinical Terrain of Immunotherapies in Heterogeneous Pancreatic Cancer: Unravelling Challenges and Opportunities," published last year. 🌟 Pancreatic cancer poses formidable challenges, with its heterogeneous nature complicating treatment strategies. Our comprehensive review explores the evolving landscape of immunotherapies in combating this relentless disease. 💡 From dissecting the intricate tumor microenvironment to unraveling the mechanisms of immunotherapy resistance, our article provides a roadmap for navigating the complexities of pancreatic cancer treatment. Moreover, we have reviewed most of the immunotherapy clinical trials until 2023 in pancreatic cancer. https://lnkd.in/e8nMjvPE Mélanie Herpels @journal of pathology #PancreaticCancer #Immunotherapy The Institute of Cancer Research

The Wenbin Lin Group have made advances in cancer treatment! According to their latest publication in Angewandte Chemie, the team have developed a new therapy using a BrP@MOL nanoscale layer, which enhances the effectiveness of a type of cancer treatment known as photodynamic therapy (PDT). BrP@MOL works by changing the metabolism of cancer cells, improving oxygen levels in tumors, and boosting the body's immune response to fight cancer more effectively. The pre-clinical results have been amazing. The group found the therapy had a reduction in tumor growth by over 90%, achieved a 40% cure rate, and prevented cancer from spreading to the lungs. When combined with another treatment that helps the immune system, tumor growth was reduced by more than 98%, with an 80% cure rate. This innovative approach brings new hope in the fight against cancer. See their work and be amazed -https://lnkd.in/gbJxdQ6s

🌟 Exciting Breakthrough in the Battle Against Advanced Breast Cancer! 🚀 A truly extraordinary intervention unfolded for a 52-year-old woman facing advanced breast cancer with a prognosis of just 3 years. Conducted by Professor Steven A. Rosenmberg's team at the National Institutes of Health (NIH) in Bethesda, Maryland, the procedure is nothing short of miraculous. What's turning heads? It's a cutting-edge autologous immunotropic approach, spotlighting the patient's own "tumor-infiltrating lymphocytes" or TILs. It’s an innovative approach, centering around the selection of the patient's own cells, harvested through biopsy. Following a meticulous screening process to identify the most potent TILs tailored to the patient's cancer type, these cells were cultivated in the lab. After reaching a substantial quantity (over 80 billion), they were reintroduced alongside pembrolizumab (Keytruda), a standard immunotherapeutic drug that enhances the immune system's ability to combat tumors. The outcome? 🌈 The patient is now officially CURED! Asher Mullard's publication in Nature Review Drug Discovery details these groundbreaking results: https://lnkd.in/dCgB4Xze Now, the talk of the town: Could these TILs be the catalyst for change in other cancers too? This could mark a historic turning point in the ongoing battle against cancer. #NatureMedicine #CancerResearch #immunotherapy #nature #cancer #cancerresearch #oncology #breastcancer

A *cool* new approach to molecular profiling of colorectal cancer: Small nucleolar RNAs, or snoRNAs ❄️ SnoRNAs are a family of small non-coding RNAs found to be dysregulated in several cancer types. Read study: https://ow.ly/4XY950RwaMO Because they can be detected in circulation, snoRNAs have demonstrated potential as a non-invasive biomarker for non-small cell lung cancer, clear cell renal cell carcinoma, and other cancers, but have yet to be explored in colorectal cancer. This study demonstrated the applicability of specific snoRNA profiles as a non-invasive colorectal cancer biomarker in fecal samples, highlighting the potential of this class of biomarkers for further exploration in cancer screening. Learn more about the QX600 ddPCR system here: https://ow.ly/sjMA50RxO2j #SnoRNA #ColorectalCancer #ddPCR

Australian research has demonstrated that honeybee venom, particularly its component melittin, effectively targets and destroys aggressive breast cancer cells, including triple-negative breast cancer (TNBC) and HER2-enriched subtypes. The study found that melittin rapidly disrupts cancer cell membranes and signaling pathways critical for tumor growth while sparing normal cells. Honeybee venom was also shown to enhance the effectiveness of conventional chemotherapy drugs like docetaxel. The research involved venom from honeybees and bumblebees from Perth, Ireland, and England, with honeybee venom proving consistently effective, unlike bumblebee venom. These findings suggest promising new avenues for treating hard-to-treat breast cancers and highlight the need for further studies to refine treatment delivery and safety. https://lnkd.in/ggNy-Kjt

What is Metastatic Prostate Cancer? In this video, you can see how prostate cancer begins within the prostate gland. At this stage, it’s considered localized, which means it hasn’t spread to other parts of the body yet. However, if left untreated or if treatment isn’t effective, the cancer can become metastatic, spreading to areas like the bones, lymph nodes, or lungs. 🦴 💡 Prostate cancer will claim approximately 34,700 lives in the U.S. this year, making it the second-leading cause of cancer deaths among men. The good news? Advanced treatments like theranostics are providing new hope, targeting cancer cells with precision and offering an alternative to chemotherapy. 👉 Learn more about Theranostics for Metastatic Prostate Cancer - privadohealth.com

In can case you missed the live segment, you can still listen to WVON 1690 AM's “Dr. in the House with Dr. Terry Mason”, when his guest was Cancer Center member and UI Health oncologist KARINE TAWAGI,and they discussed bladder cancer. May is Bladder Cancer Awareness Month. The show aired live May 5. Tawagi practices in the Division of Hematology and Oncology at UI Health, where her clinical focus is the treatment of genitourinary cancers including but not limited to bladder, kidney, testicular and prostate cancer. Her research interests focus on clinical trials in genitourinary cancers, in addition to the use of immunotherapy in cancer treatment while developing strategies to diagnose, treat and minimize side effects related to immunotherapy. Click here to get the link to listen: https://bit.ly/3Utq3ki #bladdercancer #bladdercancerawarenessmonth #cancerresearch #clinicaltrials

Today, at the American Association of Cancer Research Annual Meeting, Nested’s lead program, NST-628, was featured in an oral presentation as part of the “New Drugs on the Horizon” series, and our CSO, Klaus Hoeflich, shared pre-clinical data on our non-degrading molecular glue and its potential to inhibit RAS- and RAF-driven cancers. https://lnkd.in/gKf_fEQt Further details on NST-628 can be found in the article “The pan-RAF-MEK non degrading molecular glue NST-628 is a potent and brain penetrant inhibitor of the RAS-MAPK pathway with activity across diverse RAS- and RAF-driven cancers“ published concurrently in Cancer Discovery. The Phase 1 study of NST-628 is now open and enrolling patients with advanced solid tumors. We are proud of our team to have achieved this significant milestone in our mission to provide cancer patients with better treatment alternatives.    For more insights, visit our website and stay tuned for more updates! #NST628 #AACR24

Watch this video where the new drugs in breast cancer treatment of the last decade are discussed by Paolo Tarantino Erika Hamilton Hope Rugo and Komal Jhaveri #breastcancer #treatment #CDK4_6 #elacestrant #trastuzumabderuxtecan #sacituzumabgovitecan #pembrolizumab #nivolumab

#transcript Jean Sachs, CEO of Living Beyond Breast Cancer, a national nonprofit organization dedicated to addressing disparities in cancer treatment and providing resources and support for individuals diagnosed with breast cancer. LBBC is part of the No One Missed breast cancer campaign, which aims to raise awareness about the importance of biomarker testing for metastatic breast cancer to help identify specific mutations in the tumor and develop a personalized treatment plan. #NoOneMissed #LBBC #PersonalizedMedicine #Biomarker #BiomarkerTesting #MBC #MetastaticBreastCancer #BreastCancer #BreastCancerResources #CancerAwareness lbbc.org https://lnkd.in/gwBCzEkK